PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 1, 2014Korean Circulation JournalOpen Access

Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does low-dose prasugrel (5 mg) improve platelet inhibitory efficacy compared to standard-dose clopidogrel (75 mg) in non-elderly, non-low body weight patients who underwent PCI?

Population

63 patients who underwent percutaneous coronary intervention, weight ≥60 kg, age <75 years, previously…

Comparison

Prasugrel 5 mg daily vs Clopidogrel 75 mg daily

Design

RCT, randomized to receive 75 mg clopidogrel (n=23) or 5 mg prasugrel (n=20)

Follow-up

30 days

Authors

HJHan‐Young JinTYTae‐Hyun YangKCKyu-Nam Choi

Discussion

Loading...

Member takes

Overview

Supports low-dose prasugrel for stronger platelet inhibition post-PCI; extends RCT evidence beyond elderly or low-weight subgroups.

Structured PICO

Does low-dose prasugrel (5 mg) improve platelet inhibitory efficacy compared to standard-dose clopidogrel (75 mg) in non-elderly, non-low body weight patients who underwent PCI?

P
Population
63 patients who underwent percutaneous coronary intervention, weight ≥60 kg, age <75 years, previously receiving 100 mg aspirin and 75 mg clopidogrel daily.
I
Intervention
Prasugrel 5 mg daily
C
Comparator
Clopidogrel 75 mg daily (with an additional reference group receiving prasugrel 10 mg daily)
O
Outcome
P2Y12 reaction unit (PRU) at 30 dayssurrogate

Low-dose prasugrel (5 mg) provides more potent platelet inhibition than standard-dose clopidogrel (75 mg) in non-elderly, non-low body weight patients after PCI.

Cite This Study

Jin et al. (2014) studied this question.

synapsesocial.com/papers/69f29d371b51e2fbf0187496https://doi.org/10.4070/kcj.2014.44.2.82
View Full Paper
Ask AI
Bookmark
Share